Prognostic Evaluation Value of Thyroid Function Tests plus B-type Natriuretic Peptide Tests for Patients with Heart Failure

Abstract

Objective: This research was performed to analyze the diagnostic and prognostic value of thyroid function tests plus B-type natriuretic peptide (BNP) tests in patients with heart failure (HF). Methods: This study matched 120 patients with HF (HF group) at a single institution from January 2019 and January 2021 with 120 healthy subjects (control group) (1:1 ratio) during the same period. All eligible participants received BNP and thyroid function tests. Results: Patients with HF exhibited markedly higher BNP levels than healthy controls (p < 0.05). Patients with HF showed remarkably lower concentrations of free triiodothyronine (FT₃) versus healthy controls (p < 0.05), while the concentrations of free thyroxine (FT₄) and thyroid-stimulating hormone (TSH) showed no marked alterations (p > 0.05). The aggravation of HF causes a remarkable decrease in FT₃ levels and an elevation in BNP levels (p < 0.05), while the alterations in the serum concentrations of FT₄ and TSH levels were mild (p > 0.05). After treatment, markedly elevations of FT₃ levels and a decline of BNP levels were found in the HF group (p < 0.05). Hybrid detection allows for a larger coverage of the detection area than the stand-alone test. The combined detection provided a larger area under the curve (AUC) and a higher 95% confidence interval and sensitivity versus single tests (p < 0.05), suggesting a superior diagnostic efficiency of the combined BNP and thyroid function tests. Conclusion: The combination of BNP and thyroid function tests offers a viable diagnostic alternative for HF patients, with high diagnostic efficiency and prognostic assessment value. Clinical Trial Registration: ChiCTR2200069567.